Unity Biotechnology, a Bay Area company that once won high-profile backers and a $700 million valuation for its research into aging, is now laying off every one of its remaining employees.

Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human ...

Biotech mogul Sam Waksal – who landed in prison two decades ago over the ImClone insider trading scandal that also resulted in jail time for Martha Stewart – allegedly tested an illegal ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, iteration and aligned resources are all critical drivers of breakthroughs ...

But today, Kendall has been reborn — as the glittering, glassy heart of America’s biotech industry. For many companies, Kendall Square’s status as a global center of biotechnology firms and ...

Mural Oncology is a biotechnology company that focuses on using its protein engineering platform to develop cytokine-based immunotherapies for cancer treatment. The company aims to deliver ...

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should ...

AmplifyBio, once one of central Ohio's most promising biotech firms, announced Friday that it has shut down. In a posting on its website, the company said the decision followed months of efforts ...

The layoffs are scheduled for May 28. — Nkarta, a biotech company, 53 job cuts in South San Francisco. The downsizing occurred on March 31. The job cuts were all described as permanent ...

In this article, we will be taking a look at the 7 most profitable biotech stocks to buy right ... learning for precision oncology and protein design. The RNA therapeutics sector is also booming ...

PORT-7 shows >90% tumor growth inhibition in mesothelioma models when combined with an anti-PD1 antibody. Portage plans a first-in-human trial for PORT-7 and aims to combine PORT-6 and PORT-7 to ...